drugset
drugset / Trial / NCT04645901

A Study of SYHA1805 in Healthy Adult Subjects

NCT04645901 ↗

Phase 1 Unknown 40 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a three-part Phase Ia study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of SYHA1805.

Timeline

Start
2020-12
Primary completion
2022-05
Completion
2022-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SYHA1805 Unknown — Oral

Indications

No indication recorded.